Brilacidin has shown virucidal abilities in 2 independent studies in government labs. Both the RBL and PHRI testing demonstrated responses consistent with antiviral activity against Covid 19 in addition it has been studied in about 460 patients in the ABSSSI studies.
The pre-print peer review journal articles from both labs are expected to be released soon which should include additional data, lab testing methods, summary, impressions and recommendations for additional studies including studies against other viruses such as encephalitis which currently has no effective treatment.
Glta, Farrell
PR May 19
" Brilacidin Demonstrates potent and rapid virucidal activity
· Experiment supports Brilacidin’s therapeutic potential as a COVID-19 treatment and as a prophylactic agent against COVID-19
WAKEFIELD, MA – May 19, 2020 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that its anti-SARS-CoV-2 (COVID-19) drug candidate, Brilacidin, in an in vitro experiment using VERO cells, reduced the viral titer (load) of SARS-CoV-2 by 75 percent after only 1 hour of preincubation prior to infection at a concentration of 10µM as compared to vehicle control.
These statistically significant lab results strongly support Brilacidin’s prophylactic treatment potential given the drug’s potent and rapid virucidal activity—a unique ability, different from any other known drug currently in development to treat COVID-19, to inactivate the novel coronavirus prior to host cell entry and subsequent viral replication. A majority of antiviral agents targeting SARS-CoV-2 attempt to inhibit viral replication rather than completely eliminating the virus (virustatic versus virucidal).
Additional time-dependent and concentration-dependent experiments are underway to further delineate Brilacidin’s virucidal properties against SARS-CoV-2."
The Brilacidin anti-SARS-CoV-2 research being conducted at the PHRI is separate from research being performed at a U.S. Regional Biocontainment Laboratory (RBL), both with BSL-3 testing capabilities.
“This human cell line data is highly significant, with exciting implications,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells..."
It might be better if we had a treatment that would outright kill the virus instead of trying to inhibit or block. Has anybody around here heard of this kind of drug? It would be helpful if it is already proven to be safe in humans.
News 
Market Data 
Discover 
